204 related articles for article (PubMed ID: 21215876)
21. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European urooncological group.
Calais da Silva F; Bono A; Whelan P; Brausi M; Queimadelos M; Portillo J; Kirkali Z; Robertson C
Oncology; 2003; 65 Suppl 1():24-8. PubMed ID: 12949430
[No Abstract] [Full Text] [Related]
22. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
Heidenreich A; Bracarda S; Mason M; Ozen H; Sengelov L; Van Oort I; Papandreou C; Fossa S; Hitier S; Climent MA;
Eur J Cancer; 2014 Apr; 50(6):1090-9. PubMed ID: 24485664
[TBL] [Abstract][Full Text] [Related]
23. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
24. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
Bernardi D; Talamini R; Zanetti M; Simonelli C; Vaccher E; Spina M; Tirelli U
Prostate Cancer Prostatic Dis; 2004; 7(1):45-9. PubMed ID: 14999238
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Castration-naive Metastatic Prostate Cancer.
Hamilou Z; Baciarello G; Fizazi K
Eur Urol Focus; 2017 Dec; 3(6):518-521. PubMed ID: 29500136
[TBL] [Abstract][Full Text] [Related]
26. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
Diamond E; Garcias Mdel C; Karir B; Tagawa ST
Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
[TBL] [Abstract][Full Text] [Related]
27. [Combined treatment of metastatic hormone-resistant prostate cancer].
Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
[No Abstract] [Full Text] [Related]
28. Challenges in treating advanced disease.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s366-75. PubMed ID: 24494691
[TBL] [Abstract][Full Text] [Related]
29. A review of the use of histrelin acetate in the treatment of prostate cancer.
Crawford ED
BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
[No Abstract] [Full Text] [Related]
30. STAMPEDE trial and patients with non-metastatic prostate cancer - Authors' reply.
James ND; Sydes MR; Clarke NW; Mason MD; Parmar MK
Lancet; 2016 Jul; 388(10041):235-6. PubMed ID: 27479566
[No Abstract] [Full Text] [Related]
31. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
34. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
[TBL] [Abstract][Full Text] [Related]
35. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
36. [Somatostatin analogs in the combined treatment of patients with hormone-resistant prostate cancer].
Kaprin AD; Gafanov PA; Fastovets SV
Vopr Onkol; 2009; 55(4):474-6. PubMed ID: 19947374
[No Abstract] [Full Text] [Related]
37. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
38. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
[TBL] [Abstract][Full Text] [Related]
39. [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Aktuelle Urol; 2005 Sep; 36(5):385-7. PubMed ID: 16163602
[No Abstract] [Full Text] [Related]
40. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]